Ergosta-4,6,8(14),22-tetraen-3-one is a natural ergosterol derivative suitable for biochemical experiments and drug synthesis research.

Ergosta-4,6,8(14),22-tetraen-3-one (0, 5, 10, 15, and 20 μg/ml, for 6, 12, and 24 hours) exhibited significant cytotoxicity against HepG2 cells, with IC50 values decreasing as treatment duration and concentration increased, reaching 15.6, 11.8, and 10.0 μg/ml, respectively [1].
Treatment with Ergosta-4,6,8(14),22-tetraen-3-one (0, 5, 10, and 20 μg/ml, for 12 hours) induced cell cycle arrest at the G2/M phase in HepG2 cells, with the proportion of G2/M phase cells peaking at 12 hours [1].
Treatment with Ergosta-4,6,8(14),22-tetraen-3-one (0, 5, 10, and 20 μg/ml, for 12 hours) significantly increased apoptosis in HepG2 cells, with the proportions of early and late apoptotic cells rising in correlation with the concentration of Ergosta-4,6,8(14),22-tetraen-3-one [1].
Treatment with Ergosta-4,6,8(14),22-tetraen-3-one (0, 5, 10, and 20 μg/ml, for 12 hours) led to the activation of caspase-3, -8, and -9, increased cleavage of PARP, upregulation of Bax protein expression, downregulation of Bcl-2 protein expression, and an elevated Bax/Bcl-2 ratio, indicating that ergone induces apoptosis in HepG2 cells through both intrinsic and extrinsic apoptotic pathways [1].

Ergosta-4,6,8(14),22-tetraen-3-one (10, 20 mg/kg, gavage, for 8 weeks) exhibited certain preventive effects on aristolochic acid I (AAI)-induced early kidney injury in rats. This compound significantly reduced serum creatinine, blood urea nitrogen, urinary protein, and urinary NAG levels, while also alleviating pathological damage in renal tissues [2].